Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2216 views | HTML 2629 views | ?
Sabine Taschner-Mandl1, Magdalena Schwarz1, Johanna Blaha1, Maximilian Kauer1, Florian Kromp1, Nelli Frank1, Fikret Rifatbegovic1, Tamara Weiss1, Ruth Ladenstein1,2, Martin Hohenegger3, Inge M. Ambros1, Peter F. Ambros1,2
1CCRI, Chlidren's Cancer Research Institute, Vienna, Austria
2Department of Pediatrics, Medical University of Vienna, Vienna, Austria
3Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria
Sabine Taschner-Mandl, e-mail: [email protected]
Keywords: senescence-associated-secretory-phenotype, metronomic, topotecan, MYCN-amplified neuroblastoma, NFKB1
Received: November 04, 2015 Accepted: November 17, 2015 Published: December 09, 2015
Poor prognosis and frequent relapses are major challenges for patients with high-risk neuroblastoma (NB), especially when tumors show MYCN amplification. High-dose chemotherapy triggers apoptosis, necrosis and senescence, a cellular stress response leading to permanent proliferative arrest and a typical senescence-associated secretome (SASP). SASP components reinforce growth-arrest and act immune-stimulatory, while others are tumor-promoting. We evaluated whether metronomic, i.e. long-term, repetitive low-dose, drug treatment induces senescence in vitro and in vivo. And importantly, by using the secretome as a discriminator for beneficial versus adverse effects of senescence, drugs with a tumor-inhibiting SASP were identified.
We demonstrate that metronomic application of chemotherapeutic drugs induces therapy-induced senescence, characterized by cell cycle arrest, p21WAF/CIP1 up-regulation and DNA double-strand breaks selectively in MYCN-amplified NB. Low-dose topotecan (TPT) was identified as an inducer of a favorable SASP while lacking NFKB1/p50 activation. In contrast, Bromo-deoxy-uridine induced senescent NB-cells secret a tumor-promoting SASP in a NFKB1/p50-dependent manner. Importantly, TPT-treated senescent tumor cells act growth-inhibitory in a dose-dependent manner on non-senescent tumor cells and MYCN expression is significantly reduced in vitro and in vivo. Furthermore, in a mouse xenotransplant-model for MYCN-amplified NB metronomic TPT leads to senescence selectively in tumor cells, complete or partial remission, prolonged survival and a favorable SASP.
This new mode-of-action of metronomic TPT treatment, i.e. promoting a tumor-inhibiting type of senescence in MYCN-amplified tumors, is clinically relevant as metronomic regimens are increasingly implemented in therapy protocols of various cancer entities and are considered as a feasible maintenance treatment option with moderate adverse event profiles.
Patients with metastatic neuroblastoma (NB) frequently suffer from relapse and have a high risk of succumbing to the disease. Neuroblastoma is an embryonic tumor originating from neuronal crest derived neuroblasts and is the most frequent extra-cranial solid tumor in childhood [1, 2]. High-risk neuroblastoma is characterized by tumor cell dissemination into the bone marrow, organ metastasis, amplification of the MYCN oncogene (in 40% of cases, personal communication Ladenstein R. and Pötschger U.) and recurrent segmental chromosomal aberrations [3–6]. Despite intensive multi-modal treatment, recent developments in immunotherapy and inclusion of novel targeted drugs in clinical studies, the prognosis of children with high-risk neuroblastoma is still poor, with a median 5-year overall survival between 50 and 70 percent [7–9]. Thus, there is a high interest in new therapeutic strategies that will prevent relapse and improve outcome.
In addition to apoptosis and autophagy, chemotherapeutic agents causing DNA damage result in therapy-induced senescence (TIS), a state of stable proliferative arrest, in vitro and in vivo . The physiological and pathophysiological role of cellular senescence includes organogenesis during embryonic development [11, 12] and organismal aging  as well as removal of damaged cells, as seen upon oncogene-activation in pre-malignant lesions preventing tumor initiation . Even, established tumors gradually regress in vivo when senescence is induced by p53 restoration or oncogene inactivation [15–17]. In contrast, senescent stromal cells, i.e. fibroblasts, stimulate the proliferation of premalignant and malignant epithelial cells in culture, and the tumorigenicity of premalignant cells in mouse xenografts . Thus, it is unclear whether TIS – affecting probably both, tumor and stroma – will have tumor-promoting or -inhibiting effects.
Cellular senescence is defined by several features, most importantly, cell cycle arrest accompanied by p21WAF/CIP1 and p16Ink4a up-regulation, DNA-damage response (DDR), global chromatin remodeling and epigenetic changes and a characteristic senescence-associated secretory phenotype (SASP) [13, 19–22]. Transcription of SASP factors mainly depend on p38MAPK and nuclear factor kappa B (NFκB) signaling [23, 24]. SASP components of senescent normal cells, oncogene induced senescent premalignant cells and TIS tumor cells comprise autocrine and paracrine factors reinforcing the senescence phenotype, including growth arrest. On the other hand, the SASP includes pro-inflammatory cytokines, growth factors and tissue remodeling enzymes that might act as tumor-promoters [19, 25, 26]. However, SASP-composition differs depending on the genomic background, cell type and senescence trigger. Thus, affecting immune response, apoptotic, angiogenic and mitogenic properties of nearby cells in different ways .
TIS has been studied extensively in vitro, but in vivo data are limited and contradictory. Especially the correlation of TIS with outcome in cancer patients is unclear [27–29]. Currently, several approaches are under investigation to exploit the tumor-inhibiting effects of senescence as cancer therapy . Up until now, studies have focused on TIS induced upon conventional, high-dose cytotoxic drug treatment in vitro and in vivo. Metronomic, continuous low-dose drug application might also induce TIS. In addition, treatment-related toxic side effects are likely to be reduced under metronomic, low-dose drug schedules. However, current evidence is limited to in vitro studies. We have previously shown that long-term low-dose-treatment with hydroxyurea (HU), a ribonuclease reductase inhibitor, induces senescence in primary NB cell lines in vitro . This prompted us to screen for additional drugs that induce tumor cell senescence without inducing tumor-promoting properties, such as the unfavorable compartment of the SASP. We further aimed to explore senescence induction by metronomic drug treatment as a new therapeutic strategy for high-risk NB. Therefore, we established an in vivo model for low-dose therapy-induced senescence and studied tumor-inhibiting versus-promoting roles of senescent NB-tumor cells and the underlying mechanism in vitro and in vivo.
Long-term, low-dose drug treatment results in cell cycle arrest and senescence in aggressive primary neuroblastoma cell lines
In initial dose-finding experiments 12 candidate drugs (Table 1), targeting cell cycle regulation and/or inducing DNA damage, were tested for inhibition of cell proliferation in 6 MYCN-amplified (MNA) and 5 non-amplified (nonMNA) NB cell lines (Suppl. Table S1). Two MNA and two nonMNA cell lines showing intermediate drug sensitivities among the cell lines tested were selected for further testing (Table 1 and Suppl. Table S2). Camptothecin (CPT), its derivative topotecan (TPT), distamycin A (DMA), mitoxantrone (MIT), 5-fluorouracil (5-FU), cisplatin (CIS) and the previously published senescence inducers, HU and 5-Bromo-2′-deoxyuridine (BrdU), were tested for induction of senescence in long-term cultures (three weeks) at three different concentrations around the IC50 values (Suppl. Table S2). DMA, MIT, 5-FU and CIS induced cell death, but did not yield senescent cells (Suppl. Table S2). However, HU, CPT, TPT and BrdU treatment resulted – in addition to cell death (Suppl. Figure S1a) - in senescence in both MNA, STA-NB-10 and CLB-Ma, but not in the two nonMNA cell lines (Suppl. Table S2 and Figure 1). Senescent cells had a strongly reduced DNA-synthesis rate, an enlarged, flat morphology, and high senescence-associated-beta-galactosidase (SA-β-Gal) positivity (Figure 1a and 1b). This shows that 4/12 drugs tested, i.e. HU, CPT, TPT and BrdU, lead, in addition to cell death, to senescence in aggressive MNA NB-cell lines, but not in nonMNA cell lines.
Table 1: EC50 values after 5d of treatment determined by MTT assay
Figure 1: Therapy-induced senescence and differential secretion of tumor-promoting factors in MYCN-amplified neuroblastoma cell lines. STA-NB-10 or CLB-Ma cells were cultivated in the presence of 150 or 200 μM HU, 3 or 5 nM CPT, resp., 5 nM TPT or 15 μM BrdU for 10 or 3 weeks, respectively. After re-plating a. EdU-incorporation and b. SA-β-Gal activity was analyzed (n= 3). In (b) right panel representative images of TPT-treated and control STA-NB-10 cells after SA-β-Gal staining are depicted. The 100 μm bar refers to control (CTRL) and TPT-treated cells. c, d. Cell culture supernatants of CTRL or senescent STA-NB-10 (c, d) or CLB-Ma (d) cells were (c) analyzed by cytokine antibody array for 274 cytokines and growth factors. Secreted proteins with higher than 2-fold difference to CTRL are depicted in the heatmap. Red bar highlights a cluster of unfavorable secreted factors strongly up-regulated in BrdUsen cells. (d) Quantification of MCP-3/CCL7, MMP-9, RANTES, VEGFA and PDGF-AA by ELISA or FACS-based-assays, resp., in supernatants of STA-NB-10 and CLB-Ma treated as indicated. RPMI = complete culture medium without cells. n ≥ 3. e. PCA blot of microarray gene expression data: senescent NB-cells cluster together and are distinct from differentiatiated cells. Derived from STA-NB-10 and CLB-Ma untreated control (CTRL) cells, differentiation-inducing all-trans retinoic acid (ATRA, 5 μM) treatment for 10 d, spontaneously occurring senescent F-cells (Fsp), short term-TPT for 5 d (TPTshort) and long-term senescence-inducing CPT, TPT, BrdU or HU treatment. Colored lines represent the top 3 levels of proximity acc. to network analysis derived from Qlucore software. Asterisks indicate statistically significant differences. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05.
Topotecan induces a favorable SASP independent of NFKB1/p50 activation
Senescent normal cells and neoplastic cells have been reported to produce metastasis- and angiogenesis-promoting factors as part of their SASP . As secretion of these tumor-promoting factors shall be avoided, HU-treated senescent (HUsen), CPTsen and BrdUsen STA-NB-10 cells were analyzed for their secretome. Among the top 40 differentially secreted proteins, a cluster of 12 growth factors and cytokines highly associated with aggressiveness was exclusively secreted at high levels in the BrdUsen cells, but not in the HUsen or CPTsen or the untreated control cells (Figure 1c). Further quantification confirmed that only BrdUsen STA-NB-10 cells secreted the metastasis-related factors MCP-3/CCL7 and MMP-9, the pro-inflammatory protein RANTES and angiogenesis-inducing VEGFA. In contrast, the immune-stimulatory IL-6 and NB-favorable PDGF-AA are secreted by HUsen, CPTsen and BrdUsen cells (Figure 1d). A similar, but slightly distinct, secretion pattern was observed for the CLB-Ma cell line (Figure 1d). Further gene expression profiling confirmed differences in cellular responses as mRNA expression profiles of HUsen TPTsen and CPTsen are similar and clustered more closely together in contrast to BrdUsen, which clustered more distant in both cell lines analyzed (Figure 1e). In contrast to long-term TPT treated cells, short, 5 days, treatment, or all-trans-retinoic acid (ATRA) which mainly induces neuronal-like differentiation in NB, leads only to limited expression changes (Figure 1e). These data illustrate that drug-induced senescent NB-cells undergo similar global expression changes, but secretion of predominantly tumor-promoting SASP factors was confined to BrdUsen cells.
The transcription of SASP factors was reported to be dependent on the activation of the NFκB and/or p38MAPK pathway [23, 24]. Thus, activation of these pathways was investigated in TPTsen and BrdUsen cells. p38MAPK was phosphorylated in both, TPTsen and BrdUsen cells. However, NFKB1/p50 was up-regulated and showed nuclear localization only in BrdUsen, but not in TPTsen cells (Figure 2a and 2b). The NFKB1/p50 hetero-dimerisation partner RelA/p65 was not increased (Figure 2a and 2c), suggesting that nuclear NFKB1/p50 is required for the transcription of unfavorable SASP factors in BrdUsen cells. SiRNA mediated silencing of NFKB1 reduced secretion of two NFκB target genes, MCP-3 and RANTES, significantly, but did not affect VEGFA ([32, 33] and Figure 2d and 2e). Also pharmacological inhibition of IKKβ, a kinase up-stream of NFKB1/p50, by BMS345541 similarly interfered with MCP-3 and RANTES secretion (Figure 2e). Importantly, these data demonstrate that TPTsen cells produce a more favorable SASP than BrdUsen cells and this is most likely due to a lack of NFKB1/p50 activation.
Figure 2: Secretion of unfavorable factors by BrdU-induced senescent NB cells is dependent on NFKB1/p50. a. Representative Western blot (upper panel) of CTRL and senescent STA-NB-10 and CLB-Ma treated as indicated; densidometric quantification of NFKB1/p50 relative to GAPDH (n = 3; lower panel). b, c. Representative confocal image of NFKB1/p50 or RelA/p65, Phalloidin (F-actin) and DAPI IF-staining of STA-NB-10 cells treated as indicated. d, e. NFKB1 silencing and pharmacological inhibition in BrdUsen cells: STA-NB-10 cells were treated as indicated and transfected with 2 different siRNAs targeting NFKB1 or non-silencing control siRNA or treated for 24 h with 10 μM BMS345541 (IKKβ inhibitor). Cells and supernatants were harvested 48 h after transfection (medium change 24 h post transfection). (d) Upper panel: representative WB; cells treated as indicated. Lower panel: densidometric analysis (n = 3) (e) Quantification of MCP-3/CCL7, RANTES and VEGFA by ELISA (n = 3). Asterisks indicate statistically significant differences compared to CTRL. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05; n.s. not significant.
Long-term low-dose TPT induces DNA-ds breaks and down-regulation of MYCN
Next, we examined the mechanism of action of low-dose TPT. High-dose TPT is known to act via topoisomerase I inhibition leading to DNA double strand breaks (DDB) . In order to investigate whether DDBs are present in response to the relatively low doses, i.e. 5 nM TPT applied, nuclear γH2AX foci were analyzed in short-term (4 days) and long-term (3 weeks) TPT treated STA-NB-10 cells. Upon short-term TPT treatment the mean spot count was 3-fold higher as compared to untreated control cells; in long-term TPT treated senescent NB-cells the spot count was 2.2-fold higher, but with a high variance (0 to 70 spots per nucleus) (Figure 3a and 3b). These data indicate that DDB are induced in response to low-dose TPT. Interestingly, some TPTsen cells contain several, small to large micronuclei densely packed with γH2AX positive DNA material (Figure 3a, lower panel), illustrating the elimination of irreparable DNA by packaging in micronuclei. In addition, TPTsen cells up-regulated p21WAF/CIP1, but not p16Ink4a in response to DNA damage (Figure 3c and Suppl. Figure S1b) and – in line with previous observations in senescent NB cells [31, 35] - MYCN mRNA and protein expression was abrogated (Figure 3d and 3e).
Figure 3: Long-term low-dose TPT-treated senescent NB-cells display senescence-associated markers, down-regulation of MYCN and reduce the proliferation of non-senescent NB cells in co-culture. STA-NB-10 or CLB-Ma cells, resp., were cultivated in the absence (CTRL) or presence of 5 nM TPT for 3 weeks. a. Analysis of DDB by γH2AX IF staining on cytospin preparations of STA-NB-10 cells treated as indicated (bar: 20 μm) and b. quantification by automated imaging. Dashed line in (a) represents the cytoplasmic membrane. c. Representative image scatter plots showing clipped nuclei of p21 (red) and DAPI (blue) IF-stained STA-NB-10 cells. Cutoff MFI p21=30; Insert: Box plot showing p21 mean fluorescence intensity of CTRL and TPT-treated STA-NB-10. box plots show mean, box includes 50 percentile, whiskers 10–90 percentile; d. qRT-PCR (n = 3) and e. representative Western blot analysis for MYCN. Bar diagrams depict mean +/− SEM (n = 3); f. FACS analysis: Mean percentage of CD44+ CTRL and TPT-treated STA-NB-10 (n = 3) and CLB-Ma (n = 5). g, h. After washing, senescent cells were re-plated for co-cultures together with untreated control (CTRL) cells at indicated ratios or as pure cultures. After 7 d of co-culture EdU-incorporation was measured by FACS in the CD44− fraction. (g) Representative FACS plots showing GD2 versus CD44 staining and the gating strategy. (h) Mean % EdU incorporation +/− SEM in the CD44− fraction. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05.
TPTsen NB cells inhibit growth of non-senescent NB cells in co-cultures in vitro
HU, CPT and TPTsen cells do not secrete a panel of unfavorable, tumor-promoting factors (Figure 1). Thus, we next investigated whether TPTsen cells act tumor-inhibiting or tumor-promoting, i.e. affect proliferation of non-senescent NB-cells in vitro. As cell cycle and surface marker stainings cannot be combined with SA-β-Gal staining for FACS analysis, we first confirmed CD44, known to be up-regulated in TIS NB cells, as an adequate surrogate FACS marker to identify senescent NB-cells (, Figure 3f and Suppl. Figure S2a). Next, TPTsen cells were co-cultivated with control NB-cells at different ratios for 7 days (Figure 3g and 3h). In TPTsen cells EdU incorporation and Ki-67 were drastically reduced (Figure 3h and Suppl. Figure S2b). In co-cultures, the CD44 negative fraction, containing mainly untreated, non-senescent NB-cells, showed significantly reduced EdU incorporation in a dose-dependent manner – the more TPTsen cells present, the stronger the anti-proliferative effect (Figure 3h). This proves that TPTsen tumor cells do not promote growth of non-senescent neighboring tumor cells but rather reduce their proliferation making TPT a good candidate for further in vivo testing.
Metronomic low-dose topotecan leads to prolonged survival and induces senescence in a dose-dependent manner in a xenotransplantation mouse model
Next, we aimed to establish an in vivo model for metronomic drug-induced senescence. TPT has been tested in preclinical studies in xenotransplant tumor models including NB at various doses (0.2 – 2 mg/kg/d), however, TIS was not analyzed and treatment schemes usually consisted of several cycles of treatment including treatment breaks [36, 37]. As our in vitro data support TPT as a senescence-inducing drug, when added continuously at relatively low doses (5 nM), for in vivo analysis doses ranging from 0.01 to 1 mg/kg/d were applied i.p. daily without treatment break (Figure 4a). According to pharmacodynamics data, 0.1 mg/kg/d yields tissue levels of approximately 5 nM, equivalent to the TPT concentrations used in vitro . As, to our knowledge, no syngeneic mouse model exists for NB having a MYCN amplification, a xenograft model was established by transplanting the human MNA low passage cell line STA-NB-10 subcutaneously in CD1:Foxn1nu/nu mice. Treatment was started when the mean longest axis of the xeno-transplanted tumors exceeded 1 cm (Figure 4a).
Figure 4: Senescence-induction, reduction of MYCN expression and prolonged survival in a xenograft mouse model for aggressive MYCN-amplified NB by continuous low-dose TPT treatment. a. Experimental setup: STA-NB-10 cells were inoculated s.c. in CD1nude mice and treatment was started at a mean tumor size of 0.53 +/− 0.2 cm3 by daily i.p. injection of vector control (CTRL), 1, 0.1, 0.03 or 0.01 mg/kg/d TPT for 2 or 15 weeks, resp. b. Kaplan-Meier graph showing survival of control animals (CTRL) (n = 15), 6 weeks (n = 6) and 15 weeks 0.1 TPT (n = 11) treated animals. p < 0.0001 (log rank test). c. Tumor size and d. SA-β-Gal activity after 5 days or 2 weeks of treatment, resp. (d) Upper panel: no/low 0 – 10%; intermediate 10 – 30%; high 30 – 100% of cells SA-β-Gal positive. Lower panel: representative SA-β-Gal and DAPI-staining of tumor touch preparations from 2 weeks treated xenotransplant tumors. e. CDKN1A (p21WAF/CIP1) qRT-PCR analysis of CTRL (n = 5) and 0.1 mg/kg/d TPT treated (n = 4) tumors. f. TUNEL-staining on cryo-sections of fresh frozen CTRL and TPT-exposed tumors as indicated; line represents mean +/− SEM TUNEL positive cells/image counted on 5 representative areas/tumor. g. MYCN qRT-PCR analysis of CTRL (n = 6) and 0.1 mg/kg/d TPT treated (n = 7) tumors Box plots show mean relative expression values (RQ), box includes 50 percentile, whiskers 10–90 percentile. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05.
In control mice, tumors reached the endpoint criteria (d ≥ 2 cm) within 14–22 days. When mice were treated for 6 or 15 weeks with 0.1 mg/kg/d TPT, complete (69% at 6 weeks; 91% at 15 weeks) and partial tumor remission, respectively were observed in all animals. 6 weeks 0.1 mg/kg/d treatment led to prolonged survival for another 22–46 days after treatment had been stopped (Figure 4b). If prolonged to 15 weeks, 45% stayed tumor-free for ≥ 300 days (Figure 4b). At week 2 of treatment, tumor size was reduced in a drug-dose dependent manner (Figure 4c). Importantly, in 0.1 mg/kg/d TPT exposed tumors the proportion of SA-β-Gal positive cells and CDKN1A (p21WAF/CIP1) mRNA expression was significantly elevated over control, 0.03 or 0.01 mg/kg/d TPT, however only slightly in the 1 mg/kg/d treatment group (Figure 4d and 4e). Notably, stromal cells of murine origin, i.e. endothelial cells, fibroblasts and tumor infiltrating immune cells, did not show altered SA-β-Gal activity in any of the treatment groups (Suppl. Figure S3a). Treatment-related toxic side effects, such as weight loss, splenomegaly or treatment-related deaths have not been observed in the long-term metronomic (0.1 mg/kg/d TPT) treated animals (Suppl. Figure S3b).
Thus, we were able to establish a MNA NB in vivo model for metronomic drug-induced senescence, showing that, when applied at low doses in vivo, i.e. 0.1 mg/kg/d, TPT triggers senescence in a considerably big proportion of tumor cells, but not in stromal cells and leads to a reduction of tumor size and prolonged survival.
Continuous low-dose topotecan reduces tumor aggressiveness and does not trigger expression of unfavorable SASP components in vivo
Previously, apoptosis of tumor cells and reduction of tumor vascularization have been considered as the main mechanisms of action of TPT, leading to tumor shrinkage in vivo [38, 39]. Interestingly, apoptosis was elevated to the same extent in response to 0.1 and 0.03 mg/kg/d TPT treatment (Figure 4f), but only in the 0.1 mg/kg/d treatment group senescence was detected in a high proportion of cells (Figure 4d). This indicates that in the 0.1 mg/kg/d dose group senescence probably contributes - in addition to apoptosis - to tumor remission. Next, we evaluated features of aggressiveness in TPT exposed and control tumors, including MYCN expression and proliferative activity. In line with the in vitro observation, MYCN expression was diminished by 60% (Figure 4g) and Ki-67 was lower in 0.1 mg/kg/d TPT-exposed tumors (Figure 5a).
Figure 5: Lack of NFKB1 up-regulation and BrdUsen specific secreted factors in low-dose TPT-exposed tumors in vivo. a. Quantification of Ki-67 IF-staining pattern and corresponding cell cycle state in untreated control (CTRL) and 0.1 mg/kg/d TPT-treated tumors (n = 5). b. mRNA expression in 0.1 mg/kg/d TPT exposed tumors over control tumors (each n = 4). Gene sets: left: senescence related genes (sen marker); middle: factors highly secreted exclusively in BrdUsen in vitro (SASP BrdU); right: in TPTsen and BrdUsen in vitro (SASP TPT) c. CD31 IF-staining on frozen tumor sections. Quantification of CD31+ vessel length on 30 random images/tumor (mean cumulative vessel length +/− SEM) in tumors treated as indicated. *p ≤ 0.05. d. Model: (i) Metronomic low-dose long-term TPT treatment leads to senescence via p21WAF/CIP1 without NFKB1/p50 activation. TPTsen cells down-regulate oncogenic MYCN and act tumor-inhibiting in vitro and in vivo. (ii) In contrast, BrdU treatment leads to NFKB1/p50 activation and a tumor-promoting SASP.
Evaluation of SASP expression in our in vivo model showed that while several senescence-associated markers were up-regulated in 0.1 mg/kg/d TPT exposed tumors, NFKB1/p50 and SASP-components which were exclusively up-regulated in BrdUsen cells in vitro, i.e. unfavorable factors, were not up-regulated upon metronomic TPT in vivo (Figure 1c and 5b). In turn, some of the factors typical for TPTsen cells in vitro, were up-regulated in vivo as well (Figure 5b). Also, metronomic TPT treatment led to a decreased VEGFA expression and reduced tumor vascularization (Figure 5b and 5c). Thus, our in vivo data support the notion that metronomic TPT induces senescence in a MNA NB model without up-regulation of NFKB1/p50 and production of a tumor-promoting SASP.
Evidence is accumulating that senescence contributes to cure in various murine and human malignancies [15–17, 27, 28, 40, 41]. We here provide evidence that metronomic, low dose topotecan treatment leads to DNA-damage, p21WAF/CIP1 up-regulation, senescence and tumor regression in vitro and in vivo selectively in MNA NB cells. Topotecan was identified in a small-scale drug screen. By using the SASP as a discriminator for beneficial versus adverse effects of senescence, we successfully screened for drugs that induce a favorable SASP and tumor growth-inhibitory-rather than growth-promoting properties, as demonstrated in co-culture experiments (Figure 5d). The transition to a more favorable phenotype is accompanied by a reduction of MYCN protein, frequently overexpressed in MNA tumors and a marker for bad prognosis. Thus, we propose that metronomic TPT induces a favorable type of senescence in MYCN-amplified NB which could be exploited in new therapeutic protocols.
Previous reports have mainly focused on the potential harmful nature of factors secreted by senescent cells. Anti-apoptotic and pro-proliferative effects of senescent fibrosarcoma cell supernatants have been demonstrated in previous co-culture experiments . Here, we identified drugs, HU, CPT and TPT that do not involve secretion of unfavorable SASP factors, such as MMP-9, MCP-3, RANTES and VEGF, but still induce senescence in vitro and in vivo. The fact that different drugs trigger alternative senescence pathways and cause differences in the secretion profile is in line with earlier observations [43, 44], but this study is the first to exploit this in a drug screen. Regulation of the SASP by NFκB is well established in several cell models [45–47]. We demonstrate that the massive production of tumor-promoting secreted factors in BrdUsen cells is, at least partly, due to the activation of the NFκB-pathway probably involving NFKB1/p50 homodimers, but not RelA/p65 as e.g. in ras-induced senescent fibroblasts . It is tempting to speculate that, based on our in vitro data, pharmacological inhibition of the NFκB pathway could reduce some of the tumor-promoting aspects caused by certain drugs, especially when applied at high dose or in a multi-modal setting.
While our data strongly suggest that part of the unfavorable secretome in BrdUsen NB is dependent on NFKB1, VEGFA production was not affected by NFKB1 silencing nor by pharmacological inhibition. In addition, VEGFA expression and vascularization was strongly reduced in metronomic TPT exposed tumors, an effect described earlier for TPT. It has been shown that TPT reduces HIF-1α expression leading to decreased VEGF also in NB and is associated with tumor shrinkage [48–50]. Recently, it has been demonstrated that hypoxia suppresses senescence in normal and cancer cell lines . Thus, DNA-damage induction and alleviation of hypoxic stress by TPT may both contribute to enable and induce senescence.
Metronomic drug application uses continuous low doses of drugs and has been proven effective in phase I and II clinical trials in adult and pediatric solid tumor patients [52–54]. This treatment modality has been assumed to induce tumor cell dormancy and target the tumor microenvironment by reducing the tumor vasculature and by restoring immune surveillance while having little side effects , however, the contribution of tumor cell senescence has not been investigated. We here provide evidence that tumor cell senescence might be a major contributor to the tumor-inhibiting effects observed upon low-dose metronomic TPT in MYCN-amplified tumors (Figure 5d).
TPTsen cells show down-regulation of MYCN expression in vitro and in vivo. Extra-chromosomal MYCN amplicons have been shown to be subjected to micronucleus-mediated oncogene elimination during TIS and in spontaneously occurring senescent tumor cells in NB [31, 35]. Another mechanism of MYCN down-regulation may involve transcriptional silencing by epigenetic changes taking place during senescence, as exemplified by the formation of repressive heterochromatin at several loci encoding for pro-proliferative genes [57, 58]. In turn, MYCN-down-regulation may itself cause senescence as has been demonstrated for c-myc inactivation .
In our in vitro cultures we have not observed senescent cells to resume growth upon drug withdrawal, however, a low proportion of cells may cycle very slowly as indicated by low-level DNA-synthesis. It has formerly been shown in vitro that replicative senescent fibroblasts having depleted p53 can escape senescence and re-enter cell cycle . It is speculated that upon therapy cancer cells that have accumulated additional mutations relieving cell cycle block might be capable of bypassing or even escaping senescence. Despite these pitfalls, in our study metronomic TPT-induced senescence is associated with tumor remission and prolonged survival. To further reduce relapses, future studies shall combine senescence inducing drugs with drugs targeting metabolic pathways hyperactive in senescence or DNA-repair, e.g. PARP1 inhibitors [60, 61]. Another option may be to boost paracrine activity of infiltrating CD4+ effector cells reinforcing senescence or NK-cell mediated clearance of senescent tumor cells [62, 63]. Such combination treatments could enhance the proportion of senescent cells, stabilize cell cycle arrest and/or enable elimination of senescent tumor cells.
Here, we demonstrate in a proof-of-principle study that low dose metronomic TPT does not elicit a tumor-promoting, but rather tumor-inhibiting senescence phenotype due to a lack of NFKB1/p50 activation and leads to tumor remission in an animal model for the MYCN amplified, aggressive childhood cancer neuroblastoma. This novel, so far overlooked, effect of metronomic drug treatment is confined to MYCN-amplified NB, suggesting that patients with MYCN-amplification, could benefit from this treatment modality.
MATERIALS AND METHODS
Cell lines, mouse xenotransplantation and drug-treatment
All chemicals and drugs were purchased from Sigma-Aldrich, Austria, unless stated otherwise. NB cell lines (further details see Suppl. Table 1) were maintained in culture as previously described . CLB-Ma was kindly provided by V. Combaret (Centre Leon Berard, France), Vi856 by O. Majdic (Medical University of Vienna, Austria) and SK-N-SH by B. Spengler (Fordham University, USA). GOTO was purchased from the Health Science Research Resources Bank, Japan). Sub-confluent cultures (3–5 × 105 cells/ml) were supplemented with drugs acc. to Suppl. Table 2 (all substances see Table 1; AKI #189405 and #189406 Calbiochem, Austria; Tozasertib LC Laboratories, USA). Treatment with ATRA was carried out for 10 days. Medium containing drugs was replenished 2x/week over a period of 3 or 10 weeks, resp.
For MTT assays cells were seeded at 3 × 104 – 3 × 105/ml in 96 well plates. Drugs were added to triplicate wells in an 8-point dilution series and incubated for 5 days. IC50 values were determined from log-transformed data by nonlinear regression and curve fitting.
Animal studies have been approved by the Medical University of Vienna institutional review board for animal ethics (GZ 66.009/0274-II/3b/2010). 6 to 10 weeks old female CD1Foxn1nu mice (Charles River, Germany) were kept under SPF conditions. Mice were inoculated subcutaneously with 107 STA-NB-10 cells in Matrigel (BD Biosciences, Austria) into the right flank. Mice were weighed weekly and tumor size was measured twice a week using a caliper (Tumor volume
siRNA transfection was carried out by lipofectamine-mediated reverse transfection using 2 NFKB1 targeting siRNAs (Silencer Select, s9504 and s9505) and one non-silencing siRNA (Negative control #2, all Life Technologies, Austria) as described . Medium was replenished 24 h post transfection.
SA-β-Gal staining, immunofluorescence and iFISH
SA-β-Gal staining on cultured cells or tumor touch slides was carried out at pH 5.0 using the Senescence Detection Kit (Biovision, USA) as described . Cultured SA-β-Gal stained cells were imaged using an Axiovert 40C microscope (Zeiss, Austria) and a digital camera (PL-A662; Pixelink, USA). 300 cells/sample were examined for SA-β-Gal positivity by three independent researchers. Tumor touch slides were stained in duplicate, counterstained with DAPI, pseudonymized and allocated into three classes: low (0–10% SA-β-Gal positive of all tumor cells), intermediate (10–30%) and high positivity (30–100%).
Immunofluorescence stainings were performed on 4 μm cryo-sections or cytospin preparations from in vitro cultivated cells as described . Briefly, slides were fixed with 4% PFA or methanol-acetone (1:1) and, for detection of nuclear antigens, permeabilized with 0.1% TritonX-100, 0.1% SDS, PBS or 0.3% TritonX-100. Primary antibodies were applied as indicated by the manufacturer (Suppl. Table S3). GD2 antibody (ch14.18) was FITC labelled as described in . Secondary antibodies: anti-m-Cy3, anti-rb-FITC (Dianova) or -AF594, anti-r-AF594 (Life Technologies). For F-actin, 100 nM Phalloidin-TRITC was incubated for 30 min, at RT. TUNEL staining was performed using the DeadEnd Fluorometric TUNEL kit (Promega, Austria) according to the manual.
Confocal images were acquired with a 63x objective at a Leica TCS SP8X laser scanning microscope using the software package LAS AF 4.0.0 (Leica, Germany). Automated image acquisition was done on an Axioplan fluorescence microscope (Zeiss) coupled to a motor-driven stage (Maerzhaeuser, Germany) with a 63x objective using the Metafer Software (V 3.8.6., Metasystems, Germany). Ki-67, γH2AX and p21 were quantified on 100–150 images/sample as described [65, 66]. Quantified cellular properties were nuclear size, nuclear roundness, mean signal intensity, signal background intensity and nuclear spot count. For Ki-67 cells were allocated into six classes according to cell cycle stages based on . Image scatter plots are used to visualize clipped cellular images (combined fluorescence channels), based on iCluster . Images are sorted along the axes using quantified features. CD31 was quantified on 30 random images by Image J (http://rsbweb.nih.gov/ij/download.html) and cumulative vessel lengths were calculated. TUNEL positive cells were quantified by counting positive cells in five areas of comparable cell density by three researchers. MYCN interphase-FISH was carried out on cytospin preparations as previously described .
Whole cell lysates of cells, SDS-PAGE and Western blotting were done as described . Membranes were probed with primary antibodies (see Suppl. Table S3). Anti-rb or anti-m-IRDye680 or -IRDye800 (Licor, Germany) second step antibodies, resp. were used and detected with the Licor scanner using the Odyssey software (Licor). For densidometric analysis Image Studio Lite V4.0 (Licor) was used.
mRNA expression analysis
Fresh frozen tumors were homogenized in Trizol (Invitrogen, Austria) by using the MACS Dissociator (Miltenyi, Germany) and total RNA was isolated according to the manufacturer's instructions. 104–106 in vitro cultivated cells were used for mRNA-extraction using the miRNEasy kit (Qiagen, Germany). RNA concentration was measured on a Nanodrop ND-1000 (Peqlab, Austria) and RNA integrity was determined by an Experion System (Experion RNA StdSens Analysis Kit, Bio-Rad, Austria) according to the manufacturer's protocol. Following DNAseI digestion and RNA clean-up (RNeasy MinElute Cleanup kit, Qiagen), 200 ng RNA was used for the Primeview Expression Kit (Gene Chip 3′IVT Express Kit, Affymetrix, Austria) and gene expression analysis was performed according to the manufacturer's manual. Further analysis was done in R using Bioconductor packages . CEL files were normalized using the RMA algorithm  and the probeset with the highest variance across samples was chosen for further analysis. Microarray data were deposited at the Gene Expression Omnibus (GSE59298). Qlucore Omics Explorer 3.1 (Qlucore, Sweden) was used for PCA analysis and hierarchical clustering.
For quantitative RT-PCR (qRT-PCR), 200 ng of mRNA was used for cDNA synthesis using oligo dT20 primer (VbC Biotech, Austria) and M-MLV reverse transcriptase (Promega) according to the manufacturer's protocol. For qPCR 5 ng cDNA was amplified using the Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, Germany), gene-specific primers (Suppl. Table S4) and the 7500 Fast real-time PCR System (Applied Biosystems, Austria) according to . Normalization and calculation of relative expression values were performed according to .
Cytokine antibody array and ELISA
Cells were washed, seeded at 1 × 106/well for CTRL cells or – to omit confluence – at 5 × 105/well for drug-treated senescent cells in 6 well plates. At day 1, medium was removed and 1.5 ml fresh medium/106 cells was added. After 24 h the supernatant was collected, cellular components were removed by centrifugation and supernatants were snap-frozen. Supernatants were analyzed by G4000 protein array at Raybiotech (USA) for 274 secreted factors. Further analysis was done in R using Bioconductor packages and custom scripts. Background corrected .gpr files were normalized to the internal control and genes with higher than 2-fold difference in the HU, CPT or BrdU-treated senescent NB-cells compared to control were selected for visualization.
Qantitative analysis was carried out by ELISA (MCP-3, Abnova, Taiwan), AlphaLISA (MMP-9, IL-6, RANTES; PerkinElmer, Austria) or Flowcytomix (OPG, VEGFA, PDGF-AA; eBioscience, Austria) according to the manufacturer's instructions. For detection a plate reader (Enspire, PerkinElmer) or the LSRII FACS instrument (BD) was used, respectively.
Cell cycle analysis and in vitro co-culture
Cell cultures were supplemented with 10 μM EdU for 14 h, harvested and EdU incorporation was detected by the FACS-based Click-it EdU incorporation kit (Life Technologies) according to the manufacturer's instructions.
Co-culture: 2 × 105 cells/well NB-cells were seeded in 12 well plates as single cultures or were mixed at a ratio of 1:5, 1:2 and 2:1, resp. Medium was replenished every 3 days and cells were passaged, if required. 1 week after culture start, cells were analyzed for cell cycle state by EdU incorporation. Cells were additionally stained with m-anti CD44-PE and anti GD2-FITC and acquired using the BD FACS Fortessa and the Diva software (BD).
If not otherwise stated, Graphpad prism was used for statistical analysis. For parametric analysis ANOVA and Bonferroni posthoc test, for non-parametric analysis the Kruskal-Wallis test was performed. Survival curves were generated by the product limit method of Kaplan and Meier, and compared using the Log-rank test and the Gehan-Wilcoxon test.
We would like to acknowledge Dr. J. Khan for gene expression analysis and providing access to the online expression database at http://home.ccr.cancer.gov/oncology/oncogenomics. We are grateful to C. Frech for bioinformatic help and B. Brunner-Herglotz for excellent technical support. This study was supported by the St. Anna Kinderkrebsforschung and grants of the Herzfeldersche Familienstiftung (to S. Taschner-Mandl) and of the Austrian Science Fund FWF (P-22385, to M. Hohenegger).
CONFLICTS OF INTEREST
The authors disclose no potential conflicts of interest.
Statement of clinical relevance
Despite recent promising advances in refining multi-modal (targeted) cancer therapies and immunotherapy, prognosis remains poor for many aggressive cancer entities, such as high-risk neuroblastoma. High-dose DNA-damage inducing drugs cause apoptosis, necrosis and senescence. The latter is a cellular stress response, leading to cell cycle exit and the formation of a typical senescence associated secretory phenotype (SASP), that comprises tumor-promoting as well as –inhibiting components shaping the tumor microenvironment. By chosing drugs creating a tumor-inhibiting type of senescence, such as topotecan, and applying them at a metronomic, i.e. long-term, repetitive low-dose treatment schedule we achieved complete or partial rermission and prolonged survival in xenotransplanted mice with well established tumors grown from low-passage high-risk MYCN-amplified patient derived cell lines. We here provide a new mode-of-action of metronomic regimens which are increasingly implemented in therapy protocols of various cancer entities and are considered as a feasible maintenance treatment option with moderate adverse event profiles.
This paper has been accepted based in part on peer-review conducted by another journal and the authors’ response and revisions as well as expedited peer-review in Oncotarget.
1. Brodeur GM and Bagatell R. Mechanisms of neuroblastoma regression. Nature reviews Clinical oncology. 2014; 11:704–713.
2. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, Hogarty M and Committee COGN. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatric blood & cancer. 2013; 60:985–993.
3. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V and Matthay KK. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology. 2009; 27:289–297.
4. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD and Maris JM. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British journal of cancer. 2009; 100:1471–1482.
5. Ambros IM, Brunner C, Abbasi R, Frech C and Ambros PF. Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics. Frontiers in oncology. 2014; 4:202.
6. Abbasi MR, Rifatbegovic F, Brunner C, Ladenstein R, Ambros IM and Ambros PF. Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses. Molecular oncology. 2015; 9:545–554.
7. Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K and Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. Journal of clinical oncology. 2012; 30:3264–3270.
8. Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC and Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. The lancet oncology. 2013; 14:472–480.
9. Ladenstein R. PU, Luksch R., Brock P., Castel V., Yaniv I., Papadakis V., Laureys G., Malis J., Balwierz W., Ruud E., Kogner P., Schroeder H., Forjaz De Lacerda A., Beck-Popovic M., Bician P., Garami M., Trahair T., Pearson ADJ., Valteau-Couanet D. Busulphan-Melphalan is the Superior Myeloablative Therapy (MAT) for High Risk Neuroblastoma: Results from the HR-NBL1/SIOPEN Trial. 47th Annual Meeting of the American Society of Clinical Oncology, June 2011, Chicago, USA. 2011.
10. Roninson IB. Tumor cell senescence in cancer treatment. Cancer research. 2003; 63:2705–2715.
11. Munoz-Espin D, Canamero M, Maraver A, Gomez-Lopez G, Contreras J, Murillo-Cuesta S, Rodriguez-Baeza A, Varela-Nieto I, Ruberte J, Collado M and Serrano M. Programmed cell senescence during mammalian embryonic development. Cell. 2013; 155:1104–1118.
12. Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, Yosef R, Pilpel N, Krizhanovsky V, Sharpe J and Keyes WM. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell. 2013; 155:1119–1130.
13. Lopez-Otin C, Blasco MA, Partridge L, Serrano M and Kroemer G. The hallmarks of aging. Cell. 2013; 153:1194–1217.
14. Collado M and Serrano M. Senescence in tumours: evidence from mice and humans. Nature reviews Cancer. 2010; 10:51–57.
15. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445:661–665.
16. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P and Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:13028–13033.
17. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C and Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445:656–660.
18. Davalos AR, Coppe JP, Campisi J and Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer metastasis reviews. 2010; 29:273–283.
19. Campisi J and d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nature reviews Molecular cell biology. 2007; 8:729–740.
20. Salama R, Sadaie M, Hoare M and Narita M. Cellular senescence and its effector programs. Genes & development. 2014; 28:99–114.
21. Chandra T, Ewels PA, Schoenfelder S, Furlan-Magaril M, Wingett SW, Kirschner K, Thuret JY, Andrews S, Fraser P and Reik W. Global reorganization of the nuclear landscape in senescent cells. Cell reports. 2015; 10:471–483.
22. Cruickshanks HA, McBryan T, Nelson DM, Vanderkraats ND, Shah PP, van Tuyn J, Singh Rai T, Brock C, Donahue G, Dunican DS, Drotar ME, Meehan RR, Edwards JR, Berger SL and Adams PD. Senescent cells harbour features of the cancer epigenome. Nature cell biology. 2013; 15:1495–1506.
23. Freund A, Patil CK and Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 2011; 30:1536–1548.
24. Salminen A, Kauppinen A and Kaarniranta K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cellular signalling. 2012; 24:835–845.
25. Kuilman T and Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nature reviews Cancer. 2009; 9:81–94.
26. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY and Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008; 6:2853–2868.
27. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM and Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002; 109:335–346.
28. Haugstetter AM, Loddenkemper C, Lenze D, Grone J, Standfuss C, Petersen I, Dorken B and Schmitt CA. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. British journal of cancer. 2010; 103:505–509.
29. Wang Q, Wu PC, Dong DZ, Ivanova I, Chu E, Zeliadt S, Vesselle H and Wu DY. Polyploidy road to therapy-induced cellular senescence and escape. International journal of cancer Journal international du cancer. 2013; 132:1505–1515.
30. Nardella C, Clohessy JG, Alimonti A and Pandolfi PP. Pro-senescence therapy for cancer treatment. Nature reviews Cancer. 2011; 11:503–511.
31. Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P and Ambros PF. Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. Genes, chromosomes & cancer. 2007; 46:130–142.
32. Moriuchi H, Moriuchi M and Fauci AS. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. Journal of immunology. 1997; 158:3483–3491.
33. Thompson WL and Van Eldik LJ. Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain research. 2009; 1287:47–57.
34. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS chemical biology. 2013; 8:82–95.
35. Ambros IM, Rumpler S, Luegmayr A, Hattinger CM, Strehl S, Kovar H, Gadner H and Ambros PF. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation—sign of tumour cell revertance? European journal of cancer. 1997; 33:2043–2049.
36. Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF and Houghton PJ. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clinical cancer research. 1999; 5:3617–3631.
37. Vassal G, Terrier-Lacombe MJ, Bissery MC, Venuat AM, Gyergyay F, Benard J, Morizet J, Boland I, Ardouin P, Bressac-de-Paillerets B and Gouyette A. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. British journal of cancer. 1996; 74:537–545.
38. Sordet O, Khan QA, Kohn KW and Pommier Y. Apoptosis induced by topoisomerase inhibitors. Current medicinal chemistry Anti-cancer agents. 2003; 3:271–290.
39. O’Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW and Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clinical cancer research. 1999; 5:181–187.
40. Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S and de The H. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nature medicine. 2014.
41. te Poele RH, Okorokov AL, Jardine L, Cummings J and Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer research. 2002; 62:1876–1883.
42. Porter DC, Farmaki E, Altilia S, Schools GP, West DK, Chen M, Chang BD, Puzyrev AT, Lim CU, Rokow-Kittell R, Friedhoff LT, Papavassiliou AG, Kalurupalle S, Hurteau G, Shi J, Baran PS, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:13799–13804.
43. Chang BD, Swift ME, Shen M, Fang J, Broude EV and Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:389–394.
44. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S and De Luca LM. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Experimental cell research. 1997; 234:293–299.
45. Alexander E, Hildebrand DG, Kriebs A, Obermayer K, Manz M, Rothfuss O, Schulze-Osthoff K and Essmann F. IkappaBzeta is a regulator of the senescence-associated secretory phenotype in DNA damage- and oncogene-induced senescence. Journal of cell science. 2013; 126:3738–3745.
46. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC and Lowe SW. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes & development. 2011; 25:2125–2136.
47. Rovillain E, Mansfield L, Caetano C, Alvarez-Fernandez M, Caballero OL, Medema RH, Hummerich H and Jat PS. Activation of nuclear factor-kappa B signalling promotes cellular senescence. Oncogene. 2011; 30:2356–2366.
48. Beppu K, Nakamura K, Linehan WM, Rapisarda A and Thiele CJ. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer research. 2005; 65:4775–4781.
49. Kim ES, Soffer SZ, Huang J, McCrudden KW, Yokoi A, Manley CA, Middlesworth W, Kandel JJ and Yamashiro DJ. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. Journal of pediatric surgery. 2002; 37:518–522.
50. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH and Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer research. 2004; 64:1475–1482.
51. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV and Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:13314–13318.
52. Adenis A, Ray-Coquard I, Italiano A, Chauzit E, Bui-Nguyen B, Blay JY, Tresch-Bruneel E, Fournier C, Clisant S, Amela EY, Cassier PA, Molimard M and Penel N. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. British journal of cancer. 2013; 109:2574–2578.
53. Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric blood & cancer. 2013.
54. Kumar S, Mokhtari RB, Oliveira ID, Islam S, Toledo SR, Yeger H and Baruchel S. Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts. Transl Oncol. 2013; 6:493–503.
55. Pasquier E, Kavallaris M and Andre N. Metronomic chemotherapy: new rationale for new directions. Nature reviews Clinical oncology. 2010; 7:455–465.
56. Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, Man S, Oliveira ID, Yeger H, Kerbel RS and Baruchel S. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clinical cancer research. 2011; 17:5656–5667.
57. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ and Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003; 113:703–716.
58. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M and Lowe SW. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer cell. 2010; 17:376–387.
59. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P and Campisi J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003; 22:4212–4222.
60. Das BB, Huang SY, Murai J, Rehman I, Ame JC, Sengupta S, Das SK, Majumdar P, Zhang H, Biard D, Majumder HK, Schreiber V and Pommier Y. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic acids research. 2014.
61. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Purfurst B, Walenta S, Mueller-Klieser W, Graler M, Hummel M, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013; 501:421–425.
62. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013; 494:361–365.
63. Iannello A, Thompson TW, Ardolino M, Lowe SW and Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. The Journal of experimental medicine. 2013; 210:2057–2069.
64. Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, et al. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget. 2015; 6:35247–35262. doi: 10.18632/oncotarget.6208.
65. Mouelhi A, Sayadi M, Fnaiech F, Mrad K and Ben Romdhane K. A new automatic image analysis method for assessing estrogen receptors’ status in breast tissue specimens. Computers in biology and medicine. 2013; 43:2263–2277.
66. Kromp F, Taschner-Mandl S, Schwarz M, Blaha J, Weiss T, Ambros PF and Reiter M. Semi-automated segmentation of neuroblastoma nuclei using the Gradient Energy Tensor: a user driven approach. Journal of Optical Engineering. in Press.
67. van Dierendonck JH, Keijzer R, van de Velde CJ and Cornelisse CJ. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer research. 1989; 49:2999–3006.
68. Hamilton NA and Teasdale RD. Visualizing and clustering high throughput sub-cellular localization imaging. BMC bioinformatics. 2008; 9:81.
69. Taschner S, Koesters C, Platzer B, Jorgl A, Ellmeier W, Benesch T and Strobl H. Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood. 2007; 109:971–979.
70. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome biology. 2004; 5:R80.
71. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic acids research. 2003; 31:e15.
72. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Canete A, Castel V, Janoueix-Lerosey I, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. The lancet oncology. 2009; 10:663–671.
73. Derveaux S, Vandesompele J and Hellemans J. How to do successful gene expression analysis using real-time PCR. Methods. 2010; 50:227–230.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.